EYPT
EyePoint
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
EYPT Profile
Eyepoint Pharmaceuticals Inc.
A pharmaceutical company that focused on ophthalmic treatments
Pharmaceutical
Invalid Date
06/20/2008
NASDAQ Stock Exchange
165
12-31
Common stock
480 Pleasant Street, Watertown, MA 02472
--
EyePoint Pharmaceuticals Inc., became a Delaware corporation in March 2008. Its predecessor, pSivida Limited, was incorporated as an Australian company in Western Australia in December 2000. PSivida develops tiny, extended-release, drug-delivered products. The company's products for drug delivery are designed to control and stabilize drug delivery rates over months or years. PSivida is focused on leveraging its core technology platforms, Durasert and BioSilicon, to treat chronic diseases in the back of the eye. PSivida currently has three approved products and two major product candidates in development that represent successive generations of the Durasert technology platform. Three-quarters of pSivida's sustained-release devices for the treatment of retinal diseases are currently approved by the United States or the European Union (EU).